SAVOXEPINE - STRIATAL DOPAMINE-D2-RECEPTOR OCCUPANCY IN HUMAN VOLUNTEERS MEASURED USING POSITRON EMISSION TOMOGRAPHY (PET)

被引:10
作者
LEENDERS, KL
ANTONINI, A
THOMANN, R
LOCHER, JT
MAITRE, L
GEREBTZOFF, A
BEER, HF
AMETAMEY, S
WEINREICH, R
GUT, A
GNIRSS, F
OFNER, S
SCHILLING, W
WALDMEIER, PC
机构
[1] CIBA GEIGY AG,DEPT FORSCH & ENTWICKLUNG,DIV PHARMA,CH-4002 BASEL,SWITZERLAND
[2] PAUL SCHERRER INST,PET PROGRAM,VILLIGEN,SWITZERLAND
[3] KANTONALE PSYCHIAT KLIN KONIGSFELDEN,BRUGG,SWITZERLAND
[4] KANTONSSPITAL AARAU,NUKL MED ABT,AARAU,SWITZERLAND
[5] PAUL SCHERRER INST,RADIOPHARM ABT,VILLIGEN,SWITZERLAND
关键词
SAVOXEPINE; NEUROLEPTIC DRUG; DOPAMINE-D2-RECEPTOR ANTAGONIST; POSITRON EMISSION TOMOGRAPHY; STRIATAL RECEPTOR BINDING; HEALTHY VOLUNTEERS;
D O I
10.1007/BF00315470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The extent and duration of striatal dopamine-D2 receptor occupancy by savoxepine in humans has been studied using positron emission tomography with [C-11]-raclopride, in order to investigate why the anticipated favourable ratio between its extrapyramidal and antipsychotic effects was not achieved in practice. After 0.25 mg savoxepine, striatal D2 receptor occupancy peaked at 50-60% after 24-36 h and disappeared within 6 days. After doses of 0.1 mg to 0.5 mg, D2 receptor occupancy in the putamen and caudate nucleus increased from 20 to 70% 3-7 h after administration and amounted to 40 to 75% at the peak time (20-29 h). This suggests that cumulative D2 receptor blockade would occur if equal or increasing doses of savoxepine were given repeatedly. Extrapyramidal adverse-effects would be likely to occur under such circumstances. An adequate test of the theory that preference for hippocampal dopamine D2 receptors with afford a good therapeutic ratio requires an alternative dosing regimen.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 15 条
[1]   INTERACTIONS OF CIPAZOXAPINE, CITATEPINE, ERESEPINE, AND MAROXEPINE WITH CENTRAL DOPAMINE (DA) RECEPTORS - EFFECTS ON INVIVO (H-3)SPIPERONE BINDING, DA METABOLISM, AND BEHAVIORAL PARAMETERS [J].
BISCHOFF, S ;
VASSOUT, A ;
DELINISTULA, A ;
WALDMEIER, P .
PHARMACOPSYCHIATRY, 1986, 19 (04) :306-307
[2]   BLOCKADE OF HIPPOCAMPAL DOPAMINE (DA) RECEPTORS - A TOOL FOR ANTIPSYCHOTICS WITH LOW EXTRAPYRAMIDAL SIDE-EFFECTS [J].
BISCHOFF, S ;
CHRISTEN, P ;
VASSOUT, A .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1988, 12 (04) :455-467
[3]  
BISCHOFF S, 1992, NOVEL ANTIPSYCHOTIC DRUGS, P117
[4]  
BISCHOFF S, 1988, PSYCHOPHARMACOL S, V96, pS339
[5]   NEUROLEPTIC PROFILE OF CIPAZOXAPINE (SAVOXEPINE), A NEW TETRACYCLIC DOPAMINE ANTAGONIST - CLINICAL VALIDATION OF THE HIPPOCAMPUS VERSUS STRIATUM RATIO MODEL OF DOPAMINE-RECEPTORS IN ANIMALS - A PRELIMINARY-REPORT [J].
BUTLER, B ;
BECH, P .
PHARMACOPSYCHIATRY, 1987, 20 (03) :122-126
[6]   SYNTHESIS OF [METHOXY-H-3]- AND [METHOXY-C-11]- LABELED RACLOPRIDE - SPECIFIC DOPAMINE-D2 RECEPTOR LIGANDS [J].
EHRIN, E ;
GAWELL, L ;
HOGBERG, T ;
DEPAULIS, T ;
STROM, P .
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1987, 24 (08) :931-940
[7]  
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[8]   QUANTITATIVE-ANALYSIS OF D2 DOPAMINE RECEPTOR-BINDING IN THE LIVING HUMAN-BRAIN BY PET [J].
FARDE, L ;
HALL, H ;
EHRIN, E ;
SEDVALL, G .
SCIENCE, 1986, 231 (4735) :258-261
[9]   KINETIC-ANALYSIS OF CENTRAL [C-11] RACLOPRIDE BINDING TO D2-DOPAMINE RECEPTORS STUDIED BY PET - A COMPARISON TO THE EQUILIBRIUM-ANALYSIS [J].
FARDE, L ;
ERIKSSON, L ;
BLOMQUIST, G ;
HALLDIN, C .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1989, 9 (05) :696-708
[10]   EFFICACY AND TOLERABILITY OF A NEW ANTIPSYCHOTIC COMPOUND (SAVOXEPINE) - RESULTS OF A PILOT-STUDY [J].
MOLLER, HJ ;
KISSLING, W ;
DIETZFELBINGER, T ;
STOLL, KD ;
WENDT, G .
PHARMACOPSYCHIATRY, 1989, 22 (01) :38-41